PA
BLCM

Parallel Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Parallel Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$3 – 3574
2023
Q1 		$3 Hold
10
– – ﹤0.01% 3415
2022
Q4 		$7 Hold
10
– – ﹤0.01% 3332
2022
Q3 		$0 Hold
10
– – ﹤0.01% 3616
2022
Q2 		$0 Sell
10
-50
-83% -$76 ﹤0.01% 3477
2022
Q1 		$0 Hold
60
– – ﹤0.01% 3386
2021
Q4 		$0 Hold
60
– – ﹤0.01% 3386
2021
Q3 		$0 Hold
60
– – ﹤0.01% 3348
2021
Q2 		$0 Hold
60
– – ﹤0.01% 3109
2021
Q1 		$0 Hold
60
– – ﹤0.01% 2938
2020
Q4 		$0 Hold
60
– – ﹤0.01% 2776
2020
Q3 		$0 Hold
60
– – ﹤0.01% 2722
2020
Q2 		$0 Buy
+60
New +$408 ﹤0.01% 2783

Other funds holding BLCM

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Parallel Advisors's BLCM Position: Q2 2023 in Review

Parallel Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 10 shares — an estimated $3 sold.

Parallel Advisors first reported a position in BLCM in Q2 2020 and held it in 12 quarters. The position peaked at $7 in Q4 2022. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

  • Parallel Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Parallel Advisors sold 10 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3.
  • Parallel Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2020 and held it in 12 quarters.
  • Parallel Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $7 in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.